Cystic fibrosis is a life-threatening disease that affects at least 100,000 people worldwide. It is caused by a defect in the cystic fibrosis transmembrane regulator (CFTR) gene and presently, 360 CFTR-causing mutations have been identified. Since the discovery of the CFTR gene, the expectation of developing treatments that can substantially increase the quality of life or even cure cystic fibrosis patients is growing. Yet, it is still uncertain today which developing treatments will be successful against cystic fibrosis. This study addresses this gap by assessing the opinions of over 524 cystic fibrosis researchers who participated in a global web-based survey. For most respondents, CFTR modulator therapies are the most likely to succeed in treating cystic fibrosis in the next 15 years, especially through the use of CFTR modulator combinations. Most respondents also believe that fixing or replacing the CFTR gene will lead to a cure for cystic fibrosis within 15 years, with CRISPR-Cas9 being the most likely genetic tool for this purpose.
For FULL-TEXT go to https://doi.org/10.3390/jcm11051283
Author(s): Bernardo Cabral, Vito Terlizzi, Onofrio Laselva, Carlos Conte Filho, Fabio Mota
Organization(s): Federal University of Bahia, Oswaldo Cruz Foundation, University of Foggia, Federal University of Santa Maria, Anna Meyer Children’s University
Source: Journal of Clinical Medicine
Year: 2022